Principal Financial Group
APLS

Principal Financial Group’s Apellis Pharmaceuticals APLS Stock Holding History

Principal Financial Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-499,053
Closed -$20.1M – 2164
2026
Q1 		$20.1M Buy
+499,053
New +$10.8M 0.01% 924
2025
Q1 		– Sell
-9,094
Closed -$290K – 2174
2024
Q4 		$290K Buy
9,094
+86
+1% +$2.59K ﹤0.01% 2041
2024
Q3 		$260K Sell
9,008
-3,877
-30% -$144K ﹤0.01% 2056
2024
Q2 		$494K Sell
12,885
-71,719
-85% -$3.25M ﹤0.01% 1962
2024
Q1 		$4.97M Buy
84,604
+60,741
+255% +$3.87M ﹤0.01% 1568
2023
Q4 		$1.43M Sell
23,863
-3,120
-12% -$158K ﹤0.01% 1799
2023
Q3 		$1.03M Sell
26,983
-23,973
-47% -$1.05M ﹤0.01% 1836
2023
Q2 		$4.64M Buy
50,956
+25,416
+100% +$2.19M ﹤0.01% 1550
2023
Q1 		$1.68M Sell
25,540
-47,442
-65% -$2.74M ﹤0.01% 1790
2022
Q4 		$3.77M Buy
72,982
+47,936
+191% +$2.54M ﹤0.01% 1618
2022
Q3 		$1.71M Sell
25,046
-204
-0.8% -$12.1K ﹤0.01% 1747
2022
Q2 		$1.14M Buy
25,250
+946
+4% +$43.1K ﹤0.01% 1895
2022
Q1 		$1.24M Buy
24,304
+1,696
+8% +$74.9K ﹤0.01% 1938
2021
Q4 		$1.07M Sell
22,608
-7,301
-24% -$287K ﹤0.01% 1970
2021
Q3 		$986K Buy
29,909
+972
+3% +$54.6K ﹤0.01% 2005
2021
Q2 		$1.83M Sell
28,937
-672
-2% -$34.7K ﹤0.01% 1934
2021
Q1 		$1.27M Sell
29,609
-1,215
-4% -$57.5K ﹤0.01% 1943
2020
Q4 		$1.76M Buy
30,824
+5,832
+23% +$247K ﹤0.01% 1821
2020
Q3 		$754K Sell
24,992
-1,152
-4% -$34.4K ﹤0.01% 1924
2020
Q2 		$854K Buy
26,144
+16,528
+172% +$531K ﹤0.01% 1858
2020
Q1 		$258K Buy
9,616
+318
+3% +$11.3K ﹤0.01% 2003
2019
Q4 		$285K Buy
9,298
+531
+6% +$14.7K ﹤0.01% 2062
2019
Q3 		$211K Buy
8,767
+120
+1% +$3.3K ﹤0.01% 2134
2019
Q2 		$219K Buy
+8,647
New +$176K ﹤0.01% 2129

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Principal Financial Group's APLS Position: Q2 2026 in Review

Principal Financial Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 499,053 shares — an estimated $20.1M sold.

Principal Financial Group first reported a position in APLS in Q2 2019 and held it in 24 quarters. The position peaked at $20.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Principal Financial Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Principal Financial Group sold 499,053 Apellis Pharmaceuticals shares in Q2 2026, an estimated $20.1M.
  • Principal Financial Group first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 24 quarters.
  • Principal Financial Group's Apellis Pharmaceuticals position peaked at $20.1M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.